KZR
Companies
NASDAQ
Kezar Life Sciences Inc.
Health Care
$4.46
-$2.18 (-32.44%)
Price Chart
Overview
About KZR
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Market Cap
$49.8M
Volume
210.2K
Avg. Volume
133.7K
P/E Ratio
-0.38872972
Dividend Yield
0.00%
Employees
69.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.02
Moderate Correlation
Volatility
High (0.66)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, KZR shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$49.8M
Volume210.2K
P/E Ratio-0.39
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 25, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025